MyMyelomaTeam

T-cell treatment, specifically CAR T-cell therapy, is a type of immunotherapy used to treat multiple myeloma. Here are the key points:

- Process
- T-cells, a type of immune cell, are collected from the patient.
- These T-cells are genetically modified to express a receptor called chimeric antigen receptor (CAR).
- Show Full Answer

T-cell treatment, specifically CAR T-cell therapy, is a type of immunotherapy used to treat multiple myeloma. Here are the key points:

- Process:
- T-cells, a type of immune cell, are collected from the patient.
- These T-cells are genetically modified to express a receptor called chimeric antigen receptor (CAR).
- The modified T-cells are then infused back into the patient's bloodstream.

- Function:
- The CAR allows T-cells to directly recognize and kill cancer cells without the usual activation steps.
- These CAR T-cells can live for a long time, providing ongoing protection by targeting and destroying new cancer cells.

- Benefits:
- CAR T-cell therapy can offer long-term monitoring and treatment.
- It has shown promising results, with some patients achieving complete responses.

- Approval:
- The FDA approved idecabtagene vicleucel (Abecma) for treating refractory myeloma in patients who have tried multiple other treatments.

- Side Effects:
- Potential side effects include serious allergic reactions, flu-like symptoms, nausea, diarrhea, low blood pressure, headache, rash, and eye damage.

This therapy represents a significant advancement in the treatment of multiple myeloma, offering hope for long-term remission and improved quality of life.

 This AI-generated response comes from MyMyelomaTeam and other selected sources. It is not a substitute for medical advice. Always ask your doctor about specific health concerns.

CAR-T Cell Therapy for Multiple Myeloma: What Is It? | MyMyelomaTeam

Immunotherapy for Multiple Myeloma: What To Know | MyMyelomaTeam